Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Piper Jaffray Raises Price Target on Amgen (AMGN) to $200 Following 2Q EPS Beat
July 31, 2015 10:47 AM EDTPiper Jaffray reiterated an Overweight rating on Amgen (NASDAQ: AMGN), and raised the price target to $200.00 (from $192.00), following 2Q earnings results. Total revenue of $5.37B was ahead of consensus by $64M. EPS of $2.57 beat estimates by $0.16 aided by lower than expected R&D.... More
Amgen (AMGN) PT Raised to $193 at Cowen Post Q2
July 31, 2015 6:46 AM EDTCowen analyst Eric Schmidt reiterated an Outperform rating and boosted his price target on Amgen (NASDAQ: AMGN) to $193.00 (from $189.00) amid better-than-expected Q2 results.
Schmidt commented, "Amgen reported above-consensus Q2 revenue ($5.37B vs. $5.31BE) and non-GAAP EPS ($2.57 vs. $2.41E), and raised 2015 revenue... More
Amgen (AMGN) Tops Q2 EPS by 14c, Raises FY Guidance
July 30, 2015 4:05 PM EDTAmgen (NASDAQ: AMGN) reported Q2 EPS of $2.57, $0.14 better than the analyst estimate of $2.43. Revenue for the quarter came in at $5.37 billion versus the consensus estimate of $5.32 billion.
Second Quarter 2015 Product Sales Performance
Total product sales increased 6 percent for the second quarter of 2015 versus the second quarter of 2014. The increase was driven primarily by ENBREL, Prolia, Sensipar, Kyprolis and XGEVA. Growth for the... More
